Alkermes plc - Ordinary Shares · Transaction Jul 30, 2026 · Filed Sep 4, 2026 · $15,001 to $50,000
XNAS · ALKS
-7.11% · -$3.32 · Vol 6.9M
Market closed · last close 4:00 PM ET · price as of 17:29:56 ET
Alkermes Inc. plc
PHARMACEUTICAL PREPARATIONS
$43.39
Follow $ALKS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ALKS by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredFri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET · ALKS
MethodologyALKS
Alkermes Inc. plc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
55/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ALKS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Alkermes Inc. plc
PHARMACEUTICAL PREPARATIONSListed since
1991
Employees
2K
Country
US
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$46.51
Day high
$46.53
Day low
$43.27
Previous close
$46.71
52W high
$55.22
-21.42% from high
52W low
$27.13
58% of range
Market cap
$7.3B
P/E
71.13×
EPS
$0.6100
Beta
0.21
Shares out
167.8M
Volume
6.9M
4.46× rel vol
Avg volume
1.6M
VWAP
$43.72
Price history computed in-house
1W
-5.61%
1M
-10.22%
3M
-5.71%
1Y
+56.14%
YTD
+55.08%
SMA 50 $49.09 · below
SMA 200 $38.47 · above
52W position 58%
ALKS overview
Related filings and maps
Public disclosures
Congress activity in ALKS
Official filing ↗
Federal contracts
ALKS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALKS in this window.
Lobbying spend
ALKS lobbying filings, year to date.
Registered lobbying filings matched to Alkermes Inc. plc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALKS in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ALKS.
Options
Sovereign unlock shows live options positioning for ALKS.